Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
43.82
+0.13 (0.29%)
Nov 21, 2024, 1:28 PM EST - Market open
Mirum Pharmaceuticals Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for MIRM stock have an average target of 57, with a low estimate of 38 and a high estimate of 68. The average target predicts an increase of 30.09% from the current stock price of 43.82.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MIRM stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 8 | 8 | 8 | 8 | 8 | 8 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +50.63% | Nov 13, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $65 → $68 | Strong Buy | Maintains | $65 → $68 | +55.20% | Nov 13, 2024 |
| Baird | Baird | Buy Maintains $44 → $50 | Buy | Maintains | $44 → $50 | +14.12% | Nov 13, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $47 → $49 | Buy | Maintains | $47 → $49 | +11.83% | Oct 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +50.63% | Oct 11, 2024 |
Financial Forecast
Revenue This Year
322.55M
from 186.37M
Increased by 73.07%
Revenue Next Year
412.79M
from 322.55M
Increased by 27.98%
EPS This Year
-1.86
from -4.00
EPS Next Year
-0.89
from -1.86
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 337.8M | 517.3M | 733.7M | ||
| Avg | 322.6M | 412.8M | 522.9M | ||
| Low | 305.8M | 341.0M | 390.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 81.2% | 60.4% | 77.7% | ||
| Avg | 73.1% | 28.0% | 26.7% | ||
| Low | 64.1% | 5.7% | -5.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.85 | 1.52 | 6.22 | ||
| Avg | -1.86 | -0.89 | 1.06 | ||
| Low | -2.22 | -2.38 | -2.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.